claim: Kojol received nominations.
evidence: Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels .. metabolic. metabolic. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood glucose-dependent mechanism .. insulin. insulin. beta cells. beta cells. islets of Langerhans. islets of Langerhans. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake .. They also inhibit glucagon release from the alpha cells of the islets of Langerhans .. islets of Langerhans. islets of Langerhans. glucagon. glucagon. alpha cells. alpha cells. The two main candidate molecules that fulfill criteria for an incretin are the intestinal peptides glucagon-like peptide-1 -LRB- GLP-1 -RRB- and gastric inhibitory peptide -LRB- also known as  : glucose-dependent insulinotropic polypeptide or GIP -RRB- .. glucagon. glucagon. peptide. peptide. glucagon-like peptide-1. glucagon-like peptide-1. gastric inhibitory peptide. gastric inhibitory peptide. Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 -LRB- DPP-4 -RRB- ; both GLP-1 and GIP are members of the glucagon peptide superfamily .. glucagon. glucagon. peptide. peptide. dipeptidyl peptidase-4. dipeptidyl peptidase-4. `` Many factors stimulate insulin secretion , but the main one is blood glucose .. insulin. insulin. Incretins , especially GIP and GLP-1 secreted , respectively , by K and L cells in the gut are also important '' -LRB- Rang and Dale 's Pharmacology -LRB- 2015 -RRB- -RRB- .. GLP-1 -LRB- 7-36 -RRB- amide is not very useful for treatment of type 2 diabetes mellitus , since it must be administered by continuous subcutaneous infusion .. type 2 diabetes mellitus. type 2 diabetes mellitus. Several long-lasting analogs having insulinotropic activity have been developed , and three , exenatide -LRB- Byetta -RRB- and liraglutide -LRB- Victoza -RRB- , plus exenatide extended-release -LRB- Bydureon -RRB- , have been approved for use in the U.S. .. exenatide. exenatide. liraglutide. liraglutide. The main disadvantage of these GLP-1 analogs is they must be administered by subcutaneous injection .. Another approach is to inhibit the enzyme that inactivates GLP-1 and GIP , DPP-4 .. Several DPP-4 inhibitors that can be taken orally as tablets have been developed .. DPP-4 inhibitors. DPP-4 inhibitors